Last reviewed · How we verify
VX-548
At a glance
| Generic name | VX-548 |
|---|---|
| Also known as | Suzetrigine |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants (PHASE1)
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) (PHASE3)
- A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries (PHASE4)
- A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries (PHASE4)
- Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR) (PHASE2)
- Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VX-548 CI brief — competitive landscape report
- VX-548 updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI